Heron Therapeutics Management

Management criteria checks 1/4

Heron Therapeutics' CEO is Craig Collard, appointed in Apr 2023, has a tenure of 1.08 years. directly owns 0.16% of the company’s shares, worth $672.39K. The average tenure of the management team and the board of directors is 1 years and 2.7 years respectively.

Key information

Craig Collard

Chief executive officer

US$5.5k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.1yrs
CEO ownership	0.2%
Management average tenure	less than a year
Board average tenure	2.7yrs

Recent management updates

Recent updates

CEO

Craig Collard (57 yo)

1.1yrs

Tenure

US$5,486

Compensation

Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Craig Collard	CEO & Director	1.1yrs	US$5.49k	0.16% $ 672.4k
Ira Duarte	Executive VP & CFO	less than a year	US$1.76m	0.058% $ 249.2k
William Forbes	Executive VP & Chief Development Officer	less than a year	US$1.71m	0.055% $ 235.4k
Ryan Craig	Vice President of Marketing	less than a year	no data	no data
Sean Ristine	Senior Vice President of Human Resources	8.7yrs	no data	no data
Robert Sullivan	Senior VP of Oncology Care Franchise & Commercial Operations	1.3yrs	no data	no data
Jeff Cohn	Executive Director	no data	no data	no data

1.0yrs

Average Tenure

54yo

Average Age

Experienced Management: 0J4V's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Craig Collard	CEO & Director	1.3yrs	US$5.49k	0.16% $ 672.4k
Craig Johnson	Independent Director	10.3yrs	US$11.02m	0.034% $ 147.3k
Christian Waage	Independent Director	7.9yrs	US$70.51k	0.035% $ 148.3k
Susan Rodriguez	Independent Director	2.7yrs	US$65.63k	0.035% $ 150.3k
Adam Morgan	Independent Chairman	1.3yrs	US$545.53k	0.0063% $ 26.9k
Sharmila Dissanaike	Independent Director	2.7yrs	US$55.00k	0.035% $ 150.3k

2.7yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 0J4V's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Heron Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

CEO & Director recently bought US$138k worth of stock

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Executive Vice President and Chief Development Officer

Recent updates

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Heron Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$0.80 loss per share (vs US$1.67 loss in FY 2022)

Heron Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Forecast to breakeven in 2026

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

CEO & Director recently bought US$138k worth of stock

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.38 loss in 3Q 2022)

Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024

Heron Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.35 loss per share (vs US$0.55 loss in 2Q 2022)

Heron Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Executive Vice President and Chief Development Officer

Heron Therapeutics, Inc. Announces Management Changes

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.63 loss in 1Q 2022)

Heron Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Full year 2022 earnings released: US$1.67 loss per share (vs US$2.24 loss in FY 2021)

High number of new directors

Rubric Capital Management Engages with Heron Therapeutics

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2023

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Announces the Submission of Supplemental New Drug Application for ZYNRELEF

Heron Therapeutics, Inc. Provides Sales Guidance for the Year 2022

Heron Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Heron Therapeutics, Inc. Announces U.S. FDA Approval of APONVIE™ (HTX-019) for Prevention of Postoperative Nausea and Vomiting

Heron Therapeutics, Inc. announced that it has received $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC

Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.62 loss in 2Q 2021)

Heron Therapeutics, Inc. announced that it expects to receive $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC and other investors

Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

Heron Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

Heron Therapeutics, Inc., Annual General Meeting, May 24, 2022

Heron Therapeutics, Inc. Does Not Provide Financial Guidance for the Full Year 2022

Heron Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Forecast to breakeven in 2024

Heron Therapeutics, Inc. Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.64 loss in 3Q 2020)

High number of new and inexperienced directors

High number of new and inexperienced directors

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.62 loss per share (vs US$0.61 loss in 2Q 2020)

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF for the Management of Postoperative Pain for up to 72 Hours

Heron Therapeutics, Inc. announced that it expects to receive $150 million in funding from Baker Bros. Advisors LP

Heron Therapeutics Receives Approval from U.S. Food and Drug Administration for ZYNRELEF

Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2021

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.57 loss in 1Q 2020)

Full year 2020 earnings released: US$2.50 loss per share (vs US$2.50 loss in FY 2019)

Revenue beats expectations

Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery

Heron Therapeutics, Inc. Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age